Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-α2, or combination treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Addressing the room for improvement in management of acute promyelocytic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Chimeric antigen receptor-T-cellebehandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Terapeutisk cancervaccination mod hæmatologisk cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Given a proposed role for PD-L1+ and IL-10-producing B-cell subsets in promoting certain cancers, we sought to characterize the frequency and phenotype of B cells in patients with chronic myeloproliferative neoplasms (MPNs) and the influence of ruxolitinib and interferon-α2 therapy.

METHODS: We analyzed B-cell frequencies and phenotype in patients with MPNs (n=107), before and during treatment with ruxolitinib (n=29), interferon-α2 (n=21), or the two drugs in combination (COMBI) (n=42) and healthy donors (HDs) (n=52) using flow cytometry.

RESULTS: Myelofibrosis patients had lower lymphocyte counts and proportions of B cells than patients with essential thrombocytosis or polycythemia vera and HDs. The B-cell count correlated inversely with JAK2-V617F allele burden and spleen size and increased after ruxolitinib or COMBI treatment. The proportions of PD-L1+ B cells and PD-1+ B cells were significantly higher in patients with myelofibrosis or polycythemia vera than in HDs and decreased during ruxolitinib and COMBI treatment. The proportions of TNF-α+ and IL-6+ B cells were elevated in myelofibrosis patients. The proportion of IL-6+ B cells decreased, and the proportion of IL-10+ B cells increased during ruxolitinib treatment.

CONCLUSION: B-cell frequency and phenotype were altered in MPN patients. Ruxolitinib therapy had marked effects on both frequency and phenotype. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Haematology
Vol/bind103
Udgave nummer4
Sider (fra-til)351-361
ISSN0902-4441
DOI
StatusUdgivet - okt. 2019

ID: 57728420